Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blinded, Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years Old

NCT07831226 is registered in ClinicalTrials.gov with Guangzhou Patronus Biotech Co., Ltd. as lead sponsor.

NCT NCT07831226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07831226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blinded, Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years Old
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria vaccine